PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

Search

Hims & Hers Health Inc

Cerrado

SectorConsumo defensivo

56.36 6.82

Resumen

Variación precio

24h

Actual

Mínimo

55.56

Máximo

57.18

Métricas clave

By Trading Economics

Ingresos

23M

49M

Ventas

105M

586M

P/B

Media del Sector

83.485

41.373

BPA

0.2

Margen de beneficio

8.444

Empleados

1,637

EBITDA

48M

66M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-20.24% downside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.5B

13B

Apertura anterior

49.54

Cierre anterior

56.36

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

64 / 151 Clasificación en Consumer defensive

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Hims & Hers Health Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2025, 12:54 UTC

Principales Movimientos del Mercado

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

Principales Movimientos del Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 oct 2024, 15:02 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 oct 2024, 11:28 UTC

Principales Movimientos del Mercado

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

3 jun 2025, 15:03 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 may 2025, 14:24 UTC

Ganancias

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 abr 2025, 09:30 UTC

Principales Noticias

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 abr 2025, 16:53 UTC

Principales Noticias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mar 2025, 15:54 UTC

Principales Noticias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Principales Noticias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dic 2024, 17:16 UTC

Principales Noticias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Principales Noticias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dic 2024, 15:02 UTC

Principales Noticias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dic 2024, 13:47 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dic 2024, 07:00 UTC

Principales Noticias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 oct 2024, 14:45 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 13:12 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 11:45 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 10:14 UTC

Principales Noticias

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 ago 2024, 17:52 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 jun 2024, 11:00 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Hims & Hers Health Inc Esperado

Precio Objetivo

By TipRanks

-20.24% caída

Estimación a 12 meses

Media 42.09 USD  -20.24%

Máximo 68 USD

Mínimo 25 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hims & Hers Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

11 ratings

2

Comprar

7

Mantener

2

Vender

Puntuación técnica

By Trading Central

36.685 / 52.35Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

64 / 151 Clasificación en Consumo defensivo

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.